




Biosimilars in Ontario

UPDATED: FEBRUARY 25, 2021

For up to date information on Limited Use codes and indications, [click here](#) 

Molecule	Company	Indications	LU
Adalimumab			
<i>Amgevita</i>	Amgen	RA pJIA PsA AS PsO Uveitis	TBC TBC TBC TBC TBC TBC
<i>Idacio</i>	Fresenius Kabi	RA pJIA PsA AS PsO Uveitis	TBC TBC TBC TBC TBC TBC
<i>Hadlima</i>	Merck	RA pJIA PsA AS PsO Uveitis	TBC TBC TBC TBC TBC TBC
<i>Hulio</i>	BGP Pharma	RA pJIA PsA AS PsO Uveitis	TBC TBC TBC TBC TBC TBC
<i>Hyrimoz</i>	Sandoz	RA pJIA PsA AS PsO Uveitis	TBC TBC TBC TBC TBC TBC
Etanercept			
Brenzys 	Merck	RA AS PsA JIA	499 498 TBC TBC
Erelzi 	Sandoz	RA AS pJIA	512 513 514

		PsA	563
Infliximab			
Avsola 	Amgen	RA AS	
Inflectra 	Pfizer	RA AS PsA	468 469 470
Renflexis 	Merck	RA AS PsA	541 542 543
Rituximab			
Truxima 	Teva	RA initial RA renewal GPA/MPA initial GPS/MPA renewal	575 576 587 588
Riximyo 	Sandoz	RA initial RA renewal	581 582
Ruxience 	Pfizer	RA initial RA renewal GPA/MPA initial GPS/MPA renewal	583 584 585 586